title: Histone deacetylase 3 participates in self-renewal of liver cancer stem cells through histone modification.
abstract: Understanding molecular mechanisms in self-renewal of cancer stem cells (CSCs) is important for finding novel target in therapy of cancer. In this study, we explored potential effects of histone deacetylase (HDAC) on liver CSCs. Our data showed that HDAC inhibitors suppressed self-renewal and induced differentiation of liver CSCs. Furthermore, we demonstrated that HDAC3 was selectively expressed in liver CSCs and participated in self-renewal of liver CSCs via regulating expression of pluripotency factors. Overexpression of HDAC3 was associated with poor outcome of liver cancer. HDAC inhibitors could render liver CSCs sensitive to sorafenib. Taken together, our data suggest that HDAC3 plays a critical role in regulating self-renewal of liver CSCs.
authors.affiliation: Institute of Pathology and Southwest Cancer Center, Southwest Hospital, Third Military Medical University, Chongqing, China.
authors.forename: Chungang
authors.initials: C
authors.lastname: Liu
authors.forename: Limei
authors.initials: L
authors.lastname: Liu
authors.forename: Juanjuan
authors.initials: J
authors.lastname: Shan
authors.forename: Junjie
authors.initials: J
authors.lastname: Shen
authors.forename: Yanmin
authors.initials: Y
authors.lastname: Xu
authors.forename: Qianzhen
authors.initials: Q
authors.lastname: Zhang
authors.forename: Zhi
authors.initials: Z
authors.lastname: Yang
authors.forename: Lin
authors.initials: L
authors.lastname: Wu
authors.forename: Feng
authors.initials: F
authors.lastname: Xia
authors.forename: Ping
authors.initials: P
authors.lastname: Bie
authors.forename: Youhong
authors.initials: Y
authors.lastname: Cui
authors.forename: Xia
authors.initials: X
authors.lastname: Zhang
authors.forename: Xiuwu
authors.initials: X
authors.lastname: Bian
authors.forename: Cheng
authors.initials: C
authors.lastname: Qian
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002454:Cell Differentiation / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D015870:Gene Expression; D055785:Gene Knockdown Techniques; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology; D006655:Histone Deacetylases / Q000235:genetics / Q000378:metabolism*; D006657:Histones / Q000378:metabolism*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000401:mortality; D014411:Neoplastic Stem Cells / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D009536:Niacinamide / Q000031:analogs & derivatives / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use; D011379:Prognosis; D000077157:Sorafenib; D000099186:Histone Deacetylase 3
chemical_list: D000970:Antineoplastic Agents; D056572:Histone Deacetylase Inhibitors; D006655:Histone Deacetylases; D006657:Histones; D009536:Niacinamide; D010671:Phenylurea Compounds; D000077157:Sorafenib; D000099186:Histone Deacetylase 3
keywords: Cancer stem cells; HCC; HDAC3; Histone modification; Self-renewal; TSA